Current understanding of endothelial function and the role of endothelial dysfunction in cardiovascular\u00a0diseases provides the rational basis for the development of a novel field in pharmacology\u2013pharmacology\u00a0of endothelium. Although it focuses on the treatment of vascular endothelium and vascular wall, it is\u00a0therapeutically applicable to a vast range of diseases, such as atherosclerosis, and vascular complications\u00a0thereof (e.g. myocardial infarction), heart failure postoperative vascular complications, pulmonary hypertension,\u00a0microangiopathies of neurodegenerative diseases, and many others. In fact, searching for effective\u00a0endothelium\u2013targeted therapeutics may also bear new therapeutic opportunities for prevention and\u00a0treatment of diseases such as liver steatosis, chronic liver inflammation, diabetes and cancer metastasis,\u00a0that still represent unmet medical needs.<\/p>\n
It is thus clear today, that the studies on the pharmacotherapeutic mechanisms of endothelium and vascular\u00a0wall leading to the development of novel endothelium\u2013targeted therapeutics opens new therapeutic\u00a0possibilities for the treatment of many diseases. On the other hand, evaluation of the vascular safety of\u00a0drugs should constitute an important criterion in preclinical drug development.<\/p>\n
Endothelial profiling\u2013the specialized and comprehensive evaluation of the effects of chemical compounds\u00a0on endothelium\u2013is offered by JCET, a newly established academic research centre of the Jagiellonian\u00a0University, together with consortium of partners in Poland. This offer of comprehensive research\u00a0service involves also variety of disease models to study efficacy, as well as to evaluate pharmacokinetic\u00a0profile of compounds.<\/p>\n